advertisement Acting FDA Commissioner Janet Woodcock on Friday called for an independent watchdog to investigate whether any interactions between FDA staff and Biogen violated FDA policies. The committee is also seeking documents related to Biogen’s role in an FDA move last week to narrow prescribing guidelines to patients with the earliest stages of Alzheimer’s, as opposed to any patient with the disease. STAT reported that even some senior FDA officials were surprised by the decision for such a wide initial label, and a source close to Biogen told STAT that the company wanted a narrower label “from the start, but was reluctant to push back on FDA’s desire for a broader label for fear it could derail approval.”